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Mulibrey nanism is a rare growth disorder of prenatal onset caused by mutations in the TRIM37 gene, which
encodes a RING-B-box-coiled-coil protein. The pathogenetic mechanisms of mulibrey nanism are unknown. We
have used transiently transfected cells and antibodies raised against the predicted TRIM37 protein to characterize
the TRIM37 gene product and to determine its intracellular localization. We show that the human TRIM37 cDNA
encodes a peroxisomal protein with an apparent molecular weight of 130 kD. Peroxisomal localization is com-
promised in mutant protein representing the major Finnish TRIM37 mutation but is retained in the protein rep-
resenting the minor Finnish mutation. Colocalization of endogenous TRIM37 with peroxisomal markers was
observed by double immunofluorescence staining in HepG2 and human intestinal smooth muscle cell lines. In
human tissue sections, TRIM37 shows a granular cytoplasmic pattern. Endogenous TRIM37 is not imported into
peroxisomes in peroxin 1 (PEX15/5) and peroxin 5 (PEX55/5) mutant fibroblasts but is imported normally in
peroxin 7 (PEX75/5) deficient fibroblasts, giving further evidence for a peroxisomal localization of TRIM37.
Fibroblasts derived from patients with mulibrey nanism lack C-terminal TRIM37 immunoreactivity but stain
normally for both peroxisomal matrix and membrane markers, suggesting apparently normal peroxisome biogenesis
in patient fibroblasts. Taken together, this molecular evidence unequivocally indicates that TRIM37 is located in
the peroxisomes, and Mulibrey nanism thus can be classified as a new peroxisomal disorder.
Introduction
Mulibrey (muscle-liver-brain-eye) nanism (MUL [MIM
253250]) is an autosomal recessive disorder with severe
growth failure of prenatal onset, characteristic dys-
morphic features, pericardial constriction, and hepato-
megaly. Other common features include J-shaped sella
turcica, yellowish dots in the ocular fundi, slight mus-
cular weakness, cutaneous naevi flammei, and enlarge-
ment of cerebral ventricles (Perheentupa et al. 1973;
Lipsanen-Nyman 1986; Lapunzina et al. 1995). The psy-
chomotor development of patients withmulibrey nanism
is within normal limits. Wilms tumor is reported in ∼4%
of the patients (Simila¨ et al. 1980; Lipsanen-Nyman
1986; Seemanova and Bartsch 1999). Mulibrey nanism
occurs worldwide but is more common in the Finnish
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population. Of the ∼100 patients that have been diag-
nosed worldwide, 80 are from Finland.
Mutations in the TRIM37 gene (previously desig-
nated MUL) on chromosome 17q22-q23 underlie mu-
librey nanism (Avela et al. 2000). The TRIM37 cDNA
contains an open reading frame of 2,892 bp and encodes
a 964–amino acid protein with a predicted molecular
weight of 108 kD. The TRIM37 protein is a new mem-
ber of the RING-B-box-coiled-coil (RBCC) subfamily
of zinc-finger proteins. Four mutations, resulting in a
frameshift and predicting a truncated protein, have been
described in patients with mulibrey nanism (Avela et al.
2000). As yet, there seems to be no genotype-phenotype
correlation (Avela et al. 2000; authors’ unpublished
data). By RNA in situ hybridization TRIM37 has been
found to be expressed in dorsal root and trigeminal
ganglia, liver, and epithelia of multiple tissues during
early human and mouse embryogenesis (Lehesjoki et al.
2001).
The RING-finger domain identified in the TRIM37
protein is a cysteine-rich, zinc-binding domain found in
1200 proteins of diverse eukaryotes (Saurin et al. 1996).
RING proteins are localized to the nucleus and cyto-
plasm, and they mediate diverse cellular processes, such
as oncogenesis, apoptosis, viral replication, organelle
transport, cell-cycle control, and peroxisomal biogen-
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esis. Recent evidence indicates that RING-mediated pro-
tein interactions are critical for transcriptional repres-
sion and ubiquitination (Borden and Freemont 1996;
Borden 2000; Freemont 2000; Jackson et al. 2000; Joaz-
eiro and Weissman 2000). RING domains are able to
mediate protein-protein interactions, particularly the
formation of large macromolecular complexes. Thus,
their function may be to act both as molecular building
blocks and as molecular modifiers that mediate spatial
and temporal positioning and specificity in diverse cel-
lular processes (Borden and Freemont 1996; Borden
2000).
In RBCC proteins, the RING domain is associated
with another cysteine-rich, zinc-binding domain, the B-
box, followed by a coiled-coil domain. The functions
of the RBCC subfamily of RING proteins are largely
unknown, but they too have been implicated in medi-
ation of protein-protein interactions in diverse cellular
processes and compartments (Saurin et al. 1996). For
example, midin, the protein defective in X-linked Opitz
syndrome, and MURF, which acts in skeletal myoblast
differentiation in the mouse, are associated with micro-
tubules (Cainarca et al. 1999; Spencer et al. 2000). The
brain-expressed RING-finger protein BERP is another
cytoskeleton-associated RBCC protein, which has been
shown to bind class V myosins (El-Husseini and Vincent
1999). In contrast, the Caenorhabditis elegans tam-1
and lin-41 are nuclear proteins involved in transcrip-
tional regulation (Hsieh et al. 1999; Slack et al. 2000).
PML, RFP, and TIF1 have oncogenic potential when
involved in translocations and fusion proteins in man
and mouse (Takahashi et al. 1988; de The et al. 1991;
Le Douarin et al. 1995). There is growing evidence that,
in the RBCC subfamily, the RBCC domain acts as an
integral structural unit (Borden 2000; Peng et al. 2000;
Reymond et al. 2001). A recent work on a large number
of RBCC proteins, also named TRIMs (for tripartite
motif), provided evidence that the coiled-coil region is
essential for both homo-oligomerization and proper
subcellular localization of these proteins, the great ma-
jority of which were shown to localize to discrete cy-
toplasmic or nuclear structures (Reymond et al. 2001).
Recently, TRIM37was assigned to the family of TNF-
receptor-associated factor (TRAF) proteins, because it
contains a TRAF domain (Zapata et al. 2001). This
domain is responsible for the interaction of TRAF pro-
teins with other proteins, thus acting as scaffold mol-
ecules for receptors, kinases, and a variety of regulators
in signaling pathways (Aravind et al. 1999; Wajant et
al. 2001). The TRAF domain of TRIM37 binds six
known TRAF proteins and the cytosolic domains of
several TNF-family receptors in vitro, but whether this
is physiologically relevant remains unclear (Zapata et
al. 2001).
Here, we show that both exogenously expressed and
endogenous TRIM37 protein localizes to peroxisomes.
This localization is compromised in transiently ex-
pressed TRIM37, representing the major Finnish mu-
tation (Finmajor). We conclude that TRIM37 is a per-
oxisomal protein of as yet unknown function, which
allows the classification of MUL as a new peroxisomal
disorder.
Material and Methods
Construction of Expression Plasmids and Site-Directed
Mutagenesis
The KIAA0898 clone (GenBank accession number
NM_015294; Nagase et al. 1998), containing the full-
length 4,111-bp KIAA0898 cDNA, was obtained from
the Kazuka Research Institute in Japan. The cDNA insert
was excised from the vector and was subcloned at KpnI
and NotI sites of pcDNA3.1 (Invitrogen). For N-ter-
minal tagging, an EcoRI site was inserted, by PCR, 6
bp upstream of the ATG codon. The 600-bp PCR frag-
ment was ligated to pCRII (Invitrogen) and was se-
quenced. The 5′ fragment was subsequently excised with
NsiI andXhoI and was ligated to the original KIAA0898
clone in pBluescript (pBS) cut with the same enzymes.
The fragment was excised with EcoRI andNotI and was
ligated to the pAHC expression vector (kindly provided
by T. Ma¨kela¨, University of Helsinki), a derivative of
pCIneo (Promega) in frame with the N-terminal he-
magglutinin (HA) tag sequence.
Two different mutations were introduced into the
TRIM37 coding sequence by use of the QuickChange
Site-Directed mutagenesis Kit (Stratagene). Finmajor was
reproduced by deletion of base pairs 493–497 of the
coding region, and the minor Finnish mutation (Finminor)
was reproduced by deletion of a single G at 2212. The
template for Finmajor mutagenesis was the 600-bp
TRIM37 cDNA 5′ fragment in the pCRII vector from
which the mutant fragment was subcloned in frame with
the HA tag of pAHC. Finminor was introduced into the
pcDNA3.1-TRIM37 expression construct. Final mutant
constructs were verified by sequencing the entire coding
region of the cDNAs.
In Vitro Translation
In vitro translation was performed with the TnT
Quick Coupled Transcription/Translation System (Pro-
mega), with the pBS-KIAA0898 plasmid used as the tem-
plate. 35S-methionine–labeled translation products were
analyzed on 7% SDS-PAGE (Laemmli 1970), were trans-
ferred onto nitrocellulose membrane, and were visual-
ized by autoradiography.
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Cell Culture and Transfections
Cell culture media and supplements were from Sigma,
except for fetal bovine serum (Life Technologies) and
Ultroser-G (Invitrogen). COS-1 (American Type Culture
Collection [ATCC] number CRL-1650), BHK (ATCC
number CCL-10), HeLa (ATCC number CCL-2), and
HepG2 (ATCC number HB-8065) cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), L-gluta-
mine, and antibiotics. Human intestinal smooth muscle
cells (HISM cells, from ATCC) were grown in DMEM
supplemented with 15% FBS and 2% Ultroser-G. For
transfection, the cells were seeded on glass coverslips on
5-cm or 10-cm diameter plates. The next day, the cells
were transfected with 2–8 mg of the expression con-
structs per plate, by use of Fugene reagent (Roche) ac-
cording to the manufacturer’s protocol. Cells were proc-
essed for analysis 16–48 h after transfection. The human
skin-fibroblast cell lines (PBD074/PEX7/, PBD005/
PEX5/, and PBD009/PEX1/), from patients with
peroxisomal disorders, were a kind gift from G. Dodt
(Ruhr-Universita¨t Bochum, Germany). They were orig-
inally provided by A. B. Moser and H. W. Moser (Ken-
nedy Krieger Institute). All cell lines are referred to by
a peroxisome biogenesis disorder (PBD) number given
at the Kennedy Krieger Institute and were transformed
with the large T-Antigen of SV40 virus, as described
elsewhere (Dodt et al. 1995). They were grown in
DMEM with 10% FBS and were plated on gelatinized
coverslips for immunofluorescence analysis. Fibroblast
cultures were established from skin biopsies of three
Finnish patients with MUL after informed consent and
the approval of the Ethical Review Board of the Helsinki
University Hospital were given. The fibroblasts were
grown in RPMI-1640 supplemented with 15% FBS and
were plated on gelatinized coverslips at passage 2–3 for
immunofluorescence analysis.
TRIM37 Antibodies and Antibody Purification
Polyclonal antibodies against human TRIM37 were
raised by immunization of rabbits with the synthetic
peptides FPDGEQIGPEDLSFNTDENSGR (C-terminal
amino acids 942–964) and SVREAKEDEEDEEKIQNE-
DYHHE (internal amino acids 490–513) coupled to key-
hole limpet hemocyanin. The immunizations and anti-
sera preparation were carried out at Sigma Genosys. An
aliquot of each antiserum was affinity purified by use of
the peptides coupled to CNBr-Sepharose (Amersham
Pharmacia Biotech).
Western Blotting and Subcellular Fractionation
Total cell lysates were prepared in SDS lysis buffer (10
mM Tris pH 8, 100 mM NaCl, 2% Triton X-100, 1%
SDS, 1 mM EDTA) supplemented with Complete Pro-
teinase Inhibitor Cocktail (Roche). Cells were scraped
from the plates and were suspended in lysis buffer. The
lysates were passed through a 23G needle to shear DNA
and were centrifuged at 13,000g at 4C for 10 min,
and supernatants were recovered. Protein concentration
of the lysates was measured by use of the BCA Protein
Assay Reagent (Pierce). Per sample, 10–50 mg of total
protein were analyzed on SDS-PAGE and were trans-
ferred onto Hybond ECL nitrocellulose filter (Amersham
Pharmacia Biotech) by use of Bio-Rad blotting appa-
ratus. Filters were blocked in 5% nonfat dry milk in
TBS, were rinsed and were incubated with primary an-
tibodies followed by peroxidase-conjugated secondary
antibodies (Dako). Detection was performed by use of
enhanced chemiluminiscence reagents (Amersham Phar-
macia Biotech).
For subcellular fractionation, seven nontransfected 10-
cm plates and three 10-cm plates transfectedwith theHA-
tagged TRIM37 construct were washed with PBS and
homogenization buffer (25 mM HEPES pH 7.4, 0.25 M
sucrose, 1 mM EDTA, 0.1% ethanol, and proteinase in-
hibitor cocktail), were scraped off the plates, were resus-
pended in 4.0 ml of ice-cold homogenization buffer, and
were homogenized with 20 strokes in a Dounce homog-
enizer. After serial centrifugations at 1,950g, 23,500g, and
100,000g, the 23,500g pellet (light mitochondrial frac-
tion) was resuspended and subjected to Nycodenz (Axis-
Shield) gradient centrifugation according to a published
protocol (Graham and Rickwood 1997). The gradient
was centrifuged at 35,000g in Sorvall SS-34 rotor for 1
h. Fractions of 0.5 ml were collected from the bottom of
the tube by use of a peristaltic pump. The fractions were
diluted with an equal volume of homogenization buffer,
and an aliquot of each was used for enzyme-activity mea-
surements. The rest of the fractions were pelleted at
16,000g for 20 min. The organelle pellets were resus-
pended in SDS-lysis buffer and were analyzed by western
blotting as described above. The activities of the marker
enzymes acid phosphatase (lysosomes) and succinate de-
hydrogenase (mitochondria) were measured by use of
standard spectrophotometric methods according to the
recommendation of the manufacturer of the gradient me-
dia (Axis-Shield).
Fluorescence Microscopy and Immunohistochemistry
Cells grown on coverslips were rinsed with PBS and
were fixed in 4% paraformaldehyde in PBS for 20 min
at room temperature. They were permeabilized with ei-
ther 0.2% Triton X-100 or 0.05% saponin in PBS con-
taining 0.5% BSA for 5 min. Selective permeabilization
of the plasma membrane was done with 25 mg/ml dig-
itonin (Sigma) for 5 min. The primary polyclonal rabbit
antibodies used were anti-TRIM37 (see above), anti-
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Figure 1 Western blot and in vitro translation analysis of the
TRIM37 polypeptide. Polyclonal antibodies raised against (A) the C-
terminal TRIM37 peptide and (B) the internal TRIM37 peptide de-
tected a strong band at ∼130 kD in transiently transfected COS-1 cells.
The internal TRIM37 peptide antibody also detected weaker bands at
∼110 and ∼70 kD. Nontransfected control lanes are shown on the
right in panels A and B. C, In vitro transcription-translation of the
TRIM37 cDNA in the presence of [35S]methionine produced a poly-
peptide migrating at ∼130 kD. The molecular weights of the Kalei-
doscope marker (Bio-Rad) are shown. For western blot, 15 mg of total
protein per lane was analyzed on 10% SDS-PAGE. Preincubation of
the antisera with the corresponding antigenic peptides coupled to
CNBr-sepharose completely abolished the TRIM37 bands (data not
shown). The in vitro translation product was analyzed on 8% SDS-
PAGE.
PMP70 (Zymed), anti-SKL (Zymed), and anti-catalase
(Calbiochem). The primary mouse monoclonal antibod-
ies were anti-hemagglutinin (12CA5 hybridoma super-
natant, kindly provided by M. Bergman, University of
Helsinki), anti-human ALDP (MAB2162, Chemicon),
anti-human Lamp1 (H4A3, kindly provided by J. T. Au-
gust and J. E. K. Hildreth, Johns Hopkins University
School of Medicine), anti-PDI (StressGen Biotechnolo-
gies), anti-CTR433 (kindly provided by M. Bornens, In-
stitut CURIE), anti-EEA1 (Transduction Laboratories),
anti-a-tubulin (DM1A, Sigma), and anti-human mito-
chondrial antigen (MU213-UC, Biogenex). MitoTracker
Green (Molecular Probes) was used for the staining of
mitochondria in HISM cells. Secondary antibodies in-
cluded rhodamine, fluorescein, Cy2 or Cy3-conjugated
anti-mouse, and anti-rabbit-IgG (Jackson Immunochem-
icals). Antibody incubations were for 30 min at room
temperature. The coverslips were mounted withMowiol
(Calbiochem). For immunohistochemical stainings, an-
tigen affinity-purified fractions of rabbit anti-TRIM37
antisera were used at concentrations of 10 mg/ml for the
C-terminal antibody and 5 mg/ml for the internal peptide
antibody. Catalase antibody was used as a marker for
peroxisomes at a concentration of 2.6 mg/ml. Paraffin
sections from normal human ovary, liver, skin, and small
intestine were stained using the Vectastain Elite kit (Vec-
tor Laboratories) according to the manufacturer’s pro-
tocol. For the internal peptide antibody, antigen retrieval
was performed by digesting the sections with 0.05%
trypsin in PBS for 15 min at 37C. Diaminobentsidine
was used as chromogen, and the sections were coun-
terstained with hematoxylin and mounted under cov-
erslips with Mountex (Medite).
Results
Immunoblot and In Vitro Translation Analysis of the
TRIM37 Gene Product
To characterize the TRIM37 gene product, COS-1
cells were transfected with an expression construct con-
taining the full-length TRIM37 cDNA and the expressed
polypeptide was analyzed by western blotting. Antibod-
ies raised against a C-terminal peptide (amino acids
942–964) and an internal peptide (amino acids 490–
513) of the predicted TRIM37 protein detected a poly-
peptide of ∼130 kD that was absent in nontransfected
COS-1 cells (fig. 1A, 1B). In addition, an antibody
against the internal peptide showed weaker bands at
∼110 and ∼70 kD that were not present in nontrans-
fected cells (fig. 1B). The apparent size of the largest
TRIM37 polypeptide seen was larger than predicted
from the sequence (108 kD). In vitro translation was
performed to investigate whether this difference is due
to some posttranslational modification occurring in in-
tact cells. The in vitro translation product of TRIM37
was found to migrate at ∼130 kD in the SDS-PAGE
analysis (fig. 1C), suggesting that no modification that
would markedly affect the molecular weight occurs in
the TRIM37 protein.
Subcellular Localization of Exogenously Expressed
Wild-Type and Mutant TRIM37 Proteins
The subcellular localization of the protein encoded by
the TRIM37 cDNA was studied by indirect immunoflu-
orescence analysis of transiently transfected cells. BHK
and HeLa cells transfected with either nontagged (data
not shown) or hemagglutinin (HA)–tagged (fig. 2)
TRIM37 expression constructs were first labeled with
the two polyclonal anti-TRIM37 peptide antibodies or
the monoclonal anti-hemagglutinin marker. Fluores-
cence microscopy revealed a punctate cytoplasmic stain-
ing pattern with numerous small vesicular or granule-
like structures (fig. 2A1, 2B1) in most transfected cells.
The pattern was identical with both the nontagged and
HA-tagged constructs, showing that the N-terminal tag
did not interfere with the localization of the protein. This
is in line with previously published results (Zapata et al.
2001), where a N-terminally Myc-tagged TRIM37 con-
struct was used. The corresponding preimmune sera pro-
duced minimal background staining (data not shown).
After the shortest expression time (16 h) a small number
Figure 2 Distribution of exogenously expressed wild-type and mutant TRIM37 proteins in cultured cells, as visualized by indirect im-
munofluorescence analysis. TRIM37 and HA immunoreactivities (A1, B1, C1, and D1) are shown in red, and the peroxisomal markers SKL
(A2, B2, and C2) and ALDP (D2) are shown in green. Yellow color in the overlay images (A3, B3, C3, and D3) indicates overlap of the
immunoreactivities. HA-tagged wild-type TRIM37 shows peroxisomal localization in transiently transfected HeLa (A1–A3) and BHK (B1-B3)
cells. The full-length wild-type protein is localized in round vesicles throughout the cytoplasm. Consistently in several cell lines analyzed, not
all peroxisomes of a transfected cell contained TRIM37 protein. However, all TRIM37-containing vesicles stained positively for the peroxisomal
markers. Peroxisomal localization is compromised in the mutant protein representing the Finmajor mutation (C1-C3). The truncated protein is
distributed homogenously throughout the cytoplasm and the nucleus (C1) and does not colocalize with the peroxisomal marker (C2 and C3).
On the contrary, the mutant protein representing the Finminor mutation retains peroxisomal localization (D1–D3). The Finminor mutant protein
was stained with the internal TRIM37 peptide antiserum (“TRIM37/I”), the epitope of which is retained in the truncated protein. Original
magnification was 1000#.
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Figure 3 Nycodenz density gradient fractionation of the crude peroxisomal fraction of COS-1 cells transfected with HA-tagged TRIM37
construct. Western analysis of TRIM37 protein in the fractions is shown in panel C. An equal volume of each fraction containing 1–50 mg total
protein was analyzed on 8% SDS-PAGE. Diagram A shows the density (Y-axis, g/ml) of 22 fractions, as measured by weighing after centrifugal
pelleting of the organelles. Diagram B shows the amount of total protein in each fraction (Y-axis, mg/ml) and the relative intensities of TRIM37
and SKL immunoreactive bands per micrograms of total protein in the fraction (Y-axis, arbitrary units). The data for the TRIM37 and SKL
immunoreactivity curves were obtained by scanning the western blot films for TRIM37 (C) and SKL (data not shown). The peaks of both
TRIM37 and SKL immunoreactivities are within the heavy peroxisomal fractions at densities 1.22–1.25 g/ml (B, fractions 2–6). The presence
of TRIM37 in the uppermost light fractions (18–22) likely results from fragmentation of peroxisomes during the fractionation procedure
(Graham and Rickwood 1997). A biphasic distribution, such as is seen here, is observed with several peroxisomal enzyme markers, with the
activity in the lightest fractions possibly corresponding to a peroxisome subpopulation containing high levels of b-oxidation activity (Baumgart
et al. 1996). The majority of acid phosphatase activity, a marker enzyme for lysosomes, was present in the density range 1.11–1.16 g/ml (data
not shown), and the activity of the mitochondrial marker succinate dehydrogenase peaked at density ∼1.15 g/ml (data not shown).
of cells showed a few very large vesicular structures or
aggregates, instead of the small granules. The number
of cells containing these large vesicular structures in-
creased, comprising up to 50% of transfected cells with
extended expression time (data not shown).
To identify the subcellular structures that contained
TRIM37 peptide immunoreactivity, double immunoflu-
orescence stainings were performed on the transfected
COS-1, BHK, and HeLa cells by use of the TRIM37
peptide and cell organelle–specific antibodies. No col-
ocalization of TRIM37 staining was seen with late en-
dosomes/lysosomes (anti-Lamp1), early endosomes
(anti-EEA1), Golgi (anti-CTR433), endoplasmic retic-
ulum (anti-PDI), mitochondria (anti-mitochondrial an-
tigen), or microtubules (anti-a-tubulin) in any of the cell
lines (data not shown). The exclusion of TRIM37 from
these compartments is in agreement with previously pub-
lished results (Zapata et al. 2001) where, by double im-
munofluorescence, the localization of transiently trans-
fected TRIM37 was excluded frommitochondria, Golgi,
and lysosomes. In contrast, TRIM37 colocalized with
the peroxisomal markers SKL (a Ser-Lys-Leu tripeptide,
also called “peroxisomal targeting signal 1” [PTS1]) (fig.
2A1–A3, B1–B3) and PMP70 (peroxisomal membrane
protein 70; data not shown). Colocalization of peroxi-
somal markers and TRIM37 was reproducible but de-
pendent on the expression level. Colocalization was
most evident after the shortest expression times (16 h),
whereas longer times led to disruption of the small ve-
sicular morphology and the development of very large
vesicles with consequent loss of colocalization.
To further assess the subcellular localization of
TRIM37 in transfected cells, COS-1 cell lysates were
subjected to centrifugal fractionation followed by den-
sity gradient centrifugation of the light mitochondrial
fraction. TRIM37 was found to be highly concentrated
in the heavy (1.22–1.25 g/ml) peroxisomal fractions of
the gradient, as determined by western analysis of the
fractions with TRIM37 and SKL antibodies (fig. 3).
The subcellular localization of two mutant TRIM37
proteins was studied by transfection of BHK or HeLa
cells with expression constructs carrying the Finmajor
(c.493delGAAAG) or the Finminor (c.2212delG) muta-
tions identified in the cDNA of patients with MUL. The
predicted protein truncation of these mutated forms of
TRIM37 was confirmed by in vitro translation from the
corresponding mutant constructs (data not shown). The
Finmajor mutant protein, which only retains the 164 N-
terminal amino acids of the wild-type 964–amino acid
TRIM37 protein showed a homogenous cellular staining
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without a granular pattern (fig. 2C1). No colocalization
with peroxisomal markers was identified (fig. 2C1–C3).
In contrast, the truncated protein representing the Fin-
minor mutation identified in compound heterozygotes only
and retaining 737 amino acids showed a punctate cy-
toplasmic localization pattern. The pattern was similar
to that of the wild-type protein and colocalized with
peroxisomal markers (fig. 2D1–D3).
Subcellular Localization of Endogenous TRIM37
Immunoreactivity
Indirect immunofluorescence staining was performed
on a number of cell lines with TRIM37 antisera to search
for endogenous immunoreactivity. When either the in-
ternal or the C-terminal peptide TRIM37 antiserumwas
used, a punctate cytoplasmic staining pattern was ob-
served in nontransfected HeLa (data not shown), HISM
(fig. 4A, 4B, 4C, 4D1) and HepG2 (fig. 4E1, 4F1) cells,
representing staining of endogenous TRIM37. The in-
tensity of the staining was weakest in HeLa cells and
strongest in HepG2 cells. No endogenous TRIM37
staining was observed in COS-1 cells, and the preim-
mune sera produced very low nonspecific staining (data
not shown). The staining pattern comprised a large num-
ber of vesicles, from !100 to several hundred per cell,
round or slightly elongated in shape (fig. 4D1, 4E1,
4F1). In the HepG2 cells, TRIM37 staining was distrib-
uted among a smaller number of larger vesicles than
those of HISM cells. Double stainings with TRIM37 and
organelle-specific antibodies were performed on the
cells, as described above. No colocalization of TRIM37
immunoreactivity was observed with late endosomes/
lysosomes (anti-Lamp1) (fig. 4B), early endosomes (anti-
EEA) (fig. 4A), Golgi (anti-CTR433) (data not shown),
endoplasmic reticulum (anti-PDI) (data not shown), or
mitochondria (MitoTracker) (fig. 4C). On the contrary,
significant colocalization of TRIM37 immunoreactivity
was observed with peroxisomal markers, as exemplified
by colocalization with ALDP (fig. 4D1–D3, 4E1–E3,
4F1-F3). Unlike the exogenously expressed protein, the
endogenous TRIM37 immunoreactivity was consistently
present in all peroxisomes of the cell.
Immunohistochemical Localization of TRIM37 in
Human Tissue Sections
To preliminarily assess the tissue distribution of the
TRIM37 protein, immunohistochemical staining for en-
dogenous TRIM37 in paraffin-embedded human tissue
material was performed using affinity-purified internal
(I) and C-terminal (C) peptide TRIM37 antibodies and
a polyclonal anti-human catalase antibody as a marker
for peroxisomes. Both the C-terminal peptide and in-
ternal peptide TRIM37 antibodies produced a punctate
cytoplasmic staining pattern (fig. 5) similar to that of
anti-catalase antibody (fig. 5D) and compatible with per-
oxisomal localization. With the exception of liver (fig.
5A), the tissue distribution of TRIM37 immunoreactiv-
ity appeared highly cell-type specific. In the small intes-
tine, the strongest staining was observed in the smooth
muscle layer (fig. 5B). Throughout the liver, a rather
intense staining of hepatocytes was observed (fig. 5A).
It is noteworthy that endogenous TRIM37 was also de-
tected, as shown in fig. 4, in the HepG2 and HISM cell
lines derived from liver carcinoma and the intestinal
smooth muscle, respectively. The granular pattern (ar-
rows) of both TRIM37 and catalase immunoreactivity
is exemplified by sections from an area in the ovary, in
which staining was observed in the epithelial lining of
the ovarian tube (fig. 5C, D). Control sections where
primary antibody was replaced by normal rabbit IgG
showed minimal nonspecific staining (data not shown).
Immunofluorescence Analysis of Peroxisomes in
Fibroblasts of Patients with Peroxisomal Biogenesis
Disorder and Patients with MUL
To gain further insight into the peroxisomal localization
of TRIM37, immortalized fibroblasts derived from pa-
tients with known peroxisomal disorders were stained for
endogenous TRIM37. The cell lines included peroxin 1
mutant (PEX1/) cells (Zellweger syndrome, comple-
mentation group 1; generalized defect in peroxisomalma-
trix protein import), peroxin 5 mutant (PEX5/) cells
(autosomal neonatal adrenoleukodystrophy, complemen-
tation group 2; an isolated defect in PTS1- and peroxi-
somal targeting signal 2 [PTS2]-mediated import to
peroxisomes) and peroxin 7 mutant (PEX7/) cells (rhi-
zomelic chondrodysplasia punctata, complementation
group 11; an isolated defect in PTS2-mediated import).
Complete loss of peroxisomal TRIM37 immunoreactivity
was observed in PEX1/ and PEX5/ cells (fig. 6A, 6D)
whereas PEX7/ cells showed normal peroxisomal pat-
tern of TRIM37 staining (fig. 6G), suggesting that
TRIM37 is imported to peroxisomes in a PEX5-depen-
dent but PEX7-independent manner. As expected, all
three mutant cell lines stained normally for PMP70, in-
dicating the presence of peroxisome membranes (fig. 6C,
6F, 6I). PEX1/ and PEX5/ cells showed a diffuse cy-
tosolic staining of SKL (PTS1)–containingmatrix proteins
(fig. 6B, 6E), whereas SKL staining was granular in
PEX7/ cells (fig. 6H).
Fibroblasts derived from skin biopsies of three pa-
tients with MUL who were homozygous for the Finmajor
mutation were analyzed for peroxisomal morphology
and TRIM37 protein by immunofluorescence staining,
using antibodies against TRIM37, PMP70, and SKL (fig.
7). In control fibroblasts, TRIM37 peptide antibodies
produced a granular cytoplasmic staining pattern typical
of peroxisomes (fig. 7D) that colocalized with the per-
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Figure 4 Distribution of endogenous TRIM37 immunoreactivity in HISM and HepG2 cells as visualized by indirect immunofluorescence
analysis. Red color represents TRIM37 protein (A, B, C, D1, E1, and F1), the organelle markers are shown in green (A, B, C, D2, E2, and
F2) and colocalization of the immunoreactivities results are shown in yellow (D3, E3, and F3). Endogenous TRIM37 immunoreactivity is
excluded from organelles other than peroxisomes, as is exemplified by double staining for TRIM37 and endosomes (A), lysosomes (B), or
mitochondria (C) in HISM cells. Both the C-terminal peptide (TRIM37/C; D1 and F1) and internal peptide (TRIM37/I; E1) TRIM37 antisera
produced a punctate cytoplasmic staining in HISM and HepG2 cells that colocalized with the peroxisomal marker ALDP (D2, D3, E2, E3,
F2, and F3). The corresponding preimmune sera showed insignificant background staining (data not shown). Original magnificationwas 1000#.
oxisomal markers (data not shown). In agreement with
the predicted protein truncation of the Finmajor mutant
protein, TRIM37 immunoreactivity was absent in pa-
tient-derived fibroblasts (fig. 7A). The peroxisomal
membrane marker PMP70 and the peroxisomal matrix
marker SKL produced a typical peroxisomal staining
pattern in both control (fig. 7E, 7F) and patient fibro-
blasts (fig. 7B, 7C) indicating that peroxisomal mor-
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Figure 5 Immunohistochemical detection of endogenous TRIM37 in human liver (A), small intestine (B), and ovary (C) paraffin sections,
using antigen-affinity purified TRIM37 peptide antibodies. A fine granular staining pattern was observed in the smooth muscle layer of the
small intestine (B), whereas the granularity was more clustered in liver (A). In the ovary (C), TRIM37 staining was observed, among other
locations, in the epithelial layer of the ovarian tube. Anticatalase staining of the ovarian tube showed a granular cytoplasmic distribution similar
to that of TRIM37 (arrows). Both the C-terminal (C) and the internal peptide (I) antibodies produced similar staining. Nonimmune IgG controls
showed minimal nonspecific staining (data not shown). Original magnification was 630# in A and B and 1000# in C and D.
phology and the import of PTS1-containing matrix pro-
teins is not grossly affected in fibroblasts from patients
with MUL.
Discussion
TRIM37 is a new member of the RBCC protein family,
with a predicted molecular weight of 108 kD (Avela et
al. 2000). Western blot analysis of cell lysates transfected
with the TRIM37 cDNA showed that TRIM37 protein
migrates at ∼130 kD. Migration of in vitro–translated
TRIM37 was identical to that of the transiently ex-
pressed TRIM37, indicating that no major posttransla-
tional modifications occur in the TRIM37 protein. The
smaller fragments detected with the internal peptide an-
tibody most likely represent C-terminally truncated
forms of TRIM37, since they were not detected by the
C-terminal antibody. Whether they result from nonspe-
cific proteolysis or specific processing of the TRIM37
protein remains to be determined.
In the present study, we used several independentmeth-
ods to determine the subcellular localization of the
TRIM37 protein. Contrary to the sequence-based pre-
dictions that indicated a high probability of nuclear lo-
calization for TRIM37 (Avela et al. 2000), no sign of
nuclear localization was observed. Instead, TRIM37 im-
munofluorescence in transiently transfected cells showed
a cytoplasmic vesicular pattern. A similar pattern was
observed in nontransfected HeLa, HISM, and HepG2
cells, as well as by immunohistochemical staining of var-
ious tissue samples. These findings are in agreement with
recently published results in which Myc-epitope–tagged
TRIM37 was shown to be associated with unrecognized
cytosolic bodies (Zapata et al. 2001). Using four different
peroxisomal marker antibodies, we identified the cellular
compartment in which TRIM37 resided as the peroxi-
some. We could not detect colocalization with any other
cell organelle–specific markers. It is noteworthy that nor-
mal peroxisomal morphology and colocalization of
TRIM37 with peroxisomal markers were rapidly lost by
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Figure 6 Immunofluorescence analysis of endogenous TRIM37 protein in PEX1, PEX5, and PEX7 mutant fibroblast cell lines. The
mutant cell lines stained normally for PMP70, indicating the presence of peroxisome membranes (C, F, and I). PEX1/ and PEX5/ cells
showed a diffuse cytosolic SKL staining (B and E) reflecting their inability to import PTS1-containing proteins into peroxisomes. On the contrary,
SKL staining showed a normal granular pattern in the PEX7/ cells that are deficient only in PTS2-mediated import (H). Peroxisomal TRIM37
staining is completely lost in PEX1/ and PEX5/ cells (A and D) but is present in PEX7/ cells (G). The peroxisomal localization of TRIM37
in PEX7/ cells was verified by double staining with ALDP (data not shown). Original magnification was 1000#.
increasing the transfection time, which resulted in the
appearance of a few very large vesicles, possibly as a
consequence of aggregation of TRIM37 due to high ex-
pression level. A similar phenomenon occurs in yeast, in
that the number and size of peroxisomes are affected
when some of the PEX (peroxin) genes are disrupted or
overexpressed. For example, yeast cells lacking Pex11p
have only a few large peroxisomes, whereas Pex16p pro-
duces enlarged peroxisomes on overexpression (Erdmann
and Blobel 1995; Eitzen et al. 1997).We obtained further
support for the peroxisomal localization of TRIM37
from subcellular fractionation analysis, in which
TRIM37 immunoreactivity was highly enriched in the
heavy peroxisomal fractions.Wewere not able to identify
known peroxisomal targeting signals (Titorenko and Ra-
chubinski 2001) in the TRIM37 amino acid sequence.
This is not unexpected, since not all of these signals,
particularly for peroxisomal membrane proteins, have
yet been fully characterized.
All four reported mutations underlying MUL result
in a frameshift and predict protein truncation. We de-
termined the subcellular localization in transfected cells
of two mutant proteins representing disease mutations.
The Finmajor mutant TRIM37 protein, retaining 164
amino acids of the wild-type protein followed by 10
nonsense amino acids, was found to lose peroxisomal
targeting and displayed diffuse cellular staining. How-
ever, in agreement with previous results (Zapata et al.
2001), cytoplasmic vesicular localization was retained
in a deletion mutant containing the full RBCC domain
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Figure 7 Immunofluorescence analysis of fibroblasts from patients with MUL, performed by use of TRIM37 and peroxisomal marker
antibodies. The upper row shows staining for TRIM37 C-terminus (A), SKL (B), and PMP70 (C) in fibroblasts of a patient with MUL carrying
the homozygous Finmajor mutation (c.493-2ArG). The lower row shows the corresponding stainings on normal control fibroblasts (D, E, and
F). The patient fibroblasts lacked C-terminal TRIM37 staining (A), whereas a granular staining was seen in control fibroblasts (D). However,
SKL (B and E) and PMP70 (C and F) showed a similar staining pattern in patient and control fibroblasts, indicating that both number and
morphology of peroxisomes are unaltered in patient fibroblasts. Original magnification was 1000#.
(data not shown). The results are concordant with the
data of Reymond et al. (2001), who showed that the
coiled-coil region of RBCC proteins is critical for their
subcellular targeting. Alternatively, the sequence of 10
nonsense amino acids, 3 of which are cysteines, could
interfere with the targeting of the mutant polypeptide.
In contrast to the Finmajor mutant protein, the Finminor
(c.2212delG) mutant protein, retaining 737 amino acids
of the wild-type TRIM37 protein, was found to localize
to peroxisomes. When these localization data are taken
together, the primary defect in the Finmajor mutant pro-
tein seems to be disturbed targeting to peroxisomes,
whereas the Finminor mutant is correctly targeted, thus
indicating a defective function of TRIM37 in the per-
oxisome. As yet, we have not measured TRIM37 tran-
script levels in patient cells. It is possible that the mutant
mRNAs are rapidly degraded by nonsense-mediated
mRNA decay. If, however, the mRNAs are stable and
translated in significant amounts, the stability and dis-
tribution of mutant proteins in patient tissues remain
to be determined.
Peroxisomes are single-membrane–bound organelles,
!100 to 11,000 copies of which are present in nearly
all eukaryotic cells (Sacksteder and Gould 2000; Tito-
renko and Rachubinski 2001). The peroxisome matrix
is involved in numerous metabolic processes, such as
the b-oxidation of long- and very-long-chain fatty acids;
the biosynthesis of plasmalogens, cholesterol, and bile
acid; and the degradation of amino acids and purine.
Several inherited disorders are known to be due to mu-
tations in genes encoding peroxisomal proteins. These
can be broadly categorized into two groups: disorders
resulting from a single enzyme defect and those resulting
from defective biogenesis of the peroxisome due to so-
called peroxin gene mutations (Moser 2000; Sacksteder
and Gould 2000). The latter are called “peroxisome
biogenesis disorders” (PBDs), and they result in defec-
tive import of peroxisomal matrix proteins, themajority
of which are metabolic enzymes. Consequently,multiple
metabolic functions of the peroxisome are affected.
More than 20 PEX genes have been suggested to be
involved in human peroxisome biogenesis, on the basis
of complementation studies using either yeast or Chi-
nese hamster ovary cells defective in peroxisome bio-
genesis (Sacksteder and Gould 2000; Titorenko and Ra-
chubinski 2001). Eleven PEX genes have been shown
to be mutated in PBDs, and three of them, PEX2,
PEX10, and PEX12, encode proteins with a C-termi-
nally located RING domain (Slawecki et al. 1995;
Moser 2000; Sacksteder and Gould 2000). PEX2,
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PEX10, and PEX12 encode integral membrane proteins
implicated to be involved in the translocation of pro-
teins across the peroxisome membrane, possibly
through RING finger–mediated protein-protein inter-
actions (Shimozawa et al. 1992; Okumoto et al. 1998,
2000; Sacksteder and Gould 2000). We studied the lo-
calization of endogenous TRIM37 in three PEXmutant
cell lines, including PEX1/ cells, which have a gen-
eralized defect in the import of peroxisomal matrix pro-
teins, PEX5/ cells, which have a defect in both PTS1-
and PTS2-mediated import to peroxisomes, and PEX7/
 cells, which have an isolated defect in PTS2-mediated
import. Interestingly, we found that TRIM37 was not
localized to peroxisomes in PEX1/ and PEX5/ cells,
suggesting that its peroxisomal import is PTS1 depen-
dent. However, TRIM37 apparently lacks PTS1, a C-
terminal SKL, or a conservative variant of it. Further,
the fact that the Finminor mutant protein that lacks the
C-terminal 227 amino acids (see above) is targeted to
peroxisomes indicates that the C-terminus of TRIM37
is not required for correct subcellular localization.
Moreover, the full-length RBCC domain (Zapata et al.
2001; authors’ unpublished data) also shows granular
cytoplasmic localization. It is therefore possible that the
import of TRIM37 into peroxisomes is dependent on
the interaction with an as-yet-unidentified protein that
uses PTS1 to enter the peroxisomes. For example, in
yeast, the peroxisomal enzyme Eci1p may be imported
into peroxisomes through dimerization withDCi1p, an-
other peroxisomal enzyme that has a PTS1 signal (Yang
et al. 2001). Interestingly, TRIM37 staining was absent
after selective permeabilization of the plasmamembrane
with digitonin, supporting the view that TRIM37 pro-
tein resides within a membrane-bound organelle (data
not shown).
Although MUL shares features with several syn-
dromes that result from single peroxisomal enzyme de-
fects, the combination of features in MUL most closely
resemble those found in PBDs. Notably, prenatal-onset
growth failure, facial dysmorphism, hepatomegaly, pig-
mentary changes in retina and muscular weakness,
which are characteristic for patients with MUL (Per-
heentupa et al. 1973; Lipsanen-Nyman 1986), are also
typical of PDB disorders like Zellweger syndrome (MIM
214100), neonatal adrenoleukodystrophy (MIM
202370), infantile Refsum disease (MIM 266510) or
rhizomelic chondrodysplasia punctata type 1 (MIM
215100) (Moser 2000). The fact that some patients with
MUL develop fatty and cirrhotic liver and hypoplasia
of various endocrine glands (Lipsanen-Nyman 1986;M.
Lipsanen-Nyman, unpublished data) is in agreement
with a peroxisomal disease. Also, sensorineural hearing
loss has been observed in patients with MUL (M. Lip-
sanen-Nyman, unpublished data). However, patients
with MUL are neurologically intact, and their life span
is mainly affected by the cardiopathy (M. Lipsanen-
Nyman, unpublished data). Because of the overlap of
clinical features, it has been speculated previously that
MUL may be a peroxisomal disorder. Plasma concen-
trations of several fatty acids, the profile of very-long-
chain fatty acids, and de novo plasmalogen biosynthesis
in cultured fibroblasts, as well as the activity in plasma
of a peroxisomal enzyme involved in fatty acid metab-
olism, were found to be in the normal range in two
patients studied (Schutgens et al. 1994). We found that
fibroblasts of three patients with MUL lacked TRIM37
immunoreactivity but contained peroxisomes that were
apparently normal in morphology and number. The fi-
broblasts also stained normally for PTS1, suggesting
apparently unaffected import of PTS1-containing subset
of peroxisomal matrix proteins. Given the relatively
mild course of MUL, the absence of striking peroxi-
somal defects, like those seen in some of the PBD patient
fibroblasts, is not surprising.
Further study of the distribution of TRIM37 in adult
tissues is under way. Whether a tissue-specific peroxi-
somal defect is involved in pathogenesis of MUL re-
mains to be investigated. Moreover, the peroxisomal
function in patients withMUL needs to be characterized
in more detail to determine which subset of metabolic
functions are affected in this disorder. Improved knowl-
edge on TRIM37 function will not only advance our
understanding of the molecular pathogenesis of MUL
but will also give new insights into peroxisomal function
and cell biology.
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